AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of 5.96 million. The enterprise value is 6.24 million.
| Market Cap | 5.96M |
| Enterprise Value | 6.24M |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 764,238 |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +25.35% |
| Shares Change (QoQ) | +9.87% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 645,460 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 40.83 |
| PB Ratio | -1.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.41 |
| EV / Sales | 42.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.50 |
Financial Position
The company has a current ratio of 0.26
| Current Ratio | 0.26 |
| Quick Ratio | 0.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | -27.72 |
Financial Efficiency
Return on equity (ROE) is -3,138.91% and return on invested capital (ROIC) is -322.63%.
| Return on Equity (ROE) | -3,138.91% |
| Return on Assets (ROA) | -98.37% |
| Return on Invested Capital (ROIC) | -322.63% |
| Return on Capital Employed (ROCE) | 501.76% |
| Revenue Per Employee | 6,636 |
| Profits Per Employee | -691,273 |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -82.50% |
| 50-Day Moving Average | 7.13 |
| 200-Day Moving Average | 17.88 |
| Relative Strength Index (RSI) | 41.61 |
| Average Volume (20 Days) | 1,400 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of 146,000 and -15.21 million in losses. Loss per share was -24.84.
| Revenue | 146,000 |
| Gross Profit | 113,000 |
| Operating Income | -17.66M |
| Pretax Income | -15.21M |
| Net Income | -15.21M |
| EBITDA | -17.41M |
| EBIT | -17.66M |
| Loss Per Share | -24.84 |
Balance Sheet
The company has 2.25 million in cash and 2.52 million in debt, giving a net cash position of -275,000.
| Cash & Cash Equivalents | 2.25M |
| Total Debt | 2.52M |
| Net Cash | -275,000 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -3.86M |
| Book Value Per Share | -5.34 |
| Working Capital | -7.18M |
Cash Flow
In the last 12 months, operating cash flow was -12.43 million and capital expenditures -18,000, giving a free cash flow of -12.45 million.
| Operating Cash Flow | -12.43M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -12.45M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 77.40% |
| Operating Margin | -12,093.84% |
| Pretax Margin | -10,416.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.35% |
| Shareholder Yield | n/a |
| Earnings Yield | -255.12% |
| FCF Yield | -208.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 12, 2025. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jun 12, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
AIM ImmunoTech has an Altman Z-Score of -106.24 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -106.24 |
| Piotroski F-Score | 3 |